JianYu Chen | Pharmacology | Best Researcher Award

Posted on by Shen Awards

Dr. JianYu Chen | Pharmacology | Best Researcher Award

Assistant Professor at Fujian University of Traditional Chinese Medicine, China.

Dr. JianYu Chen is an Associate Professor at Fujian University of Traditional Chinese Medicine, specializing in Pharmacodynamics and the mechanism of active components of Chinese medicine. She holds a Ph.D. in Chinese Medicine from Macao University of Science and Technology and has over five years of experience in academia. Dr. Chen’s research focuses on the treatment of autoimmune and inflammatory diseases using traditional Chinese medicine, with a particular emphasis on targeted inhibition of immune-inflammatory pathways and activation of antioxidant pathways for therapeutic purposes. She has received prestigious awards, including the Macao Special Administrative Region Graduate Science and Technology Research Award, and has published extensively in high-impact journals. Dr. Chen is committed to advancing the understanding and application of traditional Chinese medicine in modern healthcare.

Professional Profiles:

Education

Dr. JianYu Chen pursued her educational journey with a Bachelor’s degree in Chinese Pharmacy from Hubei University of Traditional Chinese Medicine (2007-2011). Building upon this foundation, she obtained a Master’s degree in Chinese Pharmacy from Fujian University of Chinese Medicine (2011-2014). Driven by a passion for research and academia, she further advanced her studies, earning a Doctoral degree in Chinese Medicine from Macao University of Science and Technology (2014-2018). Throughout her academic endeavors, Dr. Chen demonstrated a keen interest in pharmacodynamics and the mechanism of active components of Chinese medicine. Her educational path laid the groundwork for her impactful contributions to the field of traditional Chinese medicine.

Professional Experience

Dr. JianYu Chen has amassed valuable professional experience in the realm of academia and research. Commencing her career as a Lecturer at Fujian University of Chinese Medicine in September 2018, she contributed significantly to the academic environment. In December 2023, she elevated to the position of Associate Professor at the same institution, further solidifying her role in academia. Dr. Chen’s professional journey underscores her commitment to advancing knowledge and research in pharmacology, particularly in the domain of autoimmune and inflammatory diseases.

Research Interest

Dr. JianYu Chen’s research interests are primarily focused on pharmacodynamics and the mechanism of active components found in traditional Chinese medicine (TCM). She is particularly interested in exploring the effects and mechanisms of TCM active components in treating autoimmune and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, and liver fibrosis. Her research endeavors aim to uncover novel therapeutic strategies derived from TCM that can effectively combat these debilitating conditions.

Award and Honors

Dr. JianYu Chen has garnered prestigious awards and honors in acknowledgment of her remarkable contributions to pharmacology and traditional Chinese medicine. Notably, she was awarded the Macao Special Administrative Region Graduate Science and Technology Research Award in 2018 for her groundbreaking research on active components from herbs against rheumatoid arthritis. This accolade, bestowed by the Macao SAR government, recognizes doctoral students who have significantly advanced knowledge in their field. Additionally, Dr. Chen received the Shanghai Plant Association Outstanding Paper Award in 2014 for her research on TCM active components against hypertrophic scars. These honors underscore Dr. Chen’s dedication to scientific inquiry and her innovative approach to addressing healthcare challenges through pharmacological research.

Research Skills

Dr. JianYu Chen possesses a diverse set of research skills honed through her extensive academic and professional experience in pharmacology and traditional Chinese medicine. Her expertise encompasses pharmacodynamics and the mechanisms of active components of Chinese medicine, with a focus on autoimmune and inflammatory diseases. Dr. Chen has demonstrated proficiency in experimental design, data analysis, and interpretation, enabling her to conduct impactful research in her field. She is adept at conducting literature reviews, experimental protocols, and statistical analyses to generate robust scientific evidence. Additionally, Dr. Chen has a strong background in molecular biology, cell culture techniques, and animal models, facilitating her investigations into the therapeutic potential of traditional Chinese medicine compounds. Her research skills enable her to contribute valuable insights to the understanding and treatment of inflammatory conditions, furthering advancements in pharmacology and healthcare.

Publications

  1. The function of sphingolipids in different pathogenesis of Alzheimer’s disease: A comprehensive review
    • Authors: Wang, X., Li, H., Sheng, Y., Qin, L., Meng, X.
    • Year: 2024
    • Citations: 2
  2. Network pharmacology-based study on mechanism of Zhi-Huang-Zhi-Tong powder in rheumatoid arthritis treatment 
    • Authors: Tian, X.-Y., Yang, Y.-J., Zheng, W.-T., Nan, L.-H., Chen, J.-Y.
    • Year: 2024
    • Citations: 0
  3. Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
    • Authors: Wilson, G., Yang, L., Su, X., Chen, J., Ma, X.
    • Year: 2023
    • Citations: 0
  4. Corrigendum to “7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signaling” [Int. Immunopharmacol. 107 (2022) 108557] (International Immunopharmacology (2022) 107, (S1567576922000418), (10.1016/j.intimp.2022.108557))
    • Authors: Chen, J., Zhu, G., Sun, Y., Ma, X., Zheng, Y.
    • Year: 2023
    • Citations: 0
  5. Corrigendum to “7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signalling” [Int. Immunopharmacol. 107 (2022) 108557] (International Immunopharmacology (2022) 112, (S1567576922006646), (10.1016/j.intimp.2022.109180))
    • Authors: Chen, J., Zhu, G., Sun, Y., Ma, X., Zheng, Y.
    • Year: 2023
    • Citations: 0
  6. Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
    • Authors: Chen, J.-Y., Tian, X.-Y., Wei, S.-S., Ma, X.-Q., Huang, M.-Q.
    • Year: 2023
    • Citations: 2
  7. Saikosaponin D alleviates cancer cachexia by directly inhibiting STAT3
    • Authors: Chen, L.-L., Xia, L.-Y., Zhang, J.-P., Guo, C., Xu, W.-H.
    • Year: 2023
    • Citations: 3
  8. Neobaicalein Inhibits Th17 Cell Differentiation Resulting in Recovery of Th17/Treg Ratio through Blocking STAT3 Signaling Activation
    • Authors: Chen, J.-Y., Yang, Y.-J., Ma, X.-Q., Zheng, Y.-F., Huang, M.-Q.
    • Year: 2023
    • Citations: 1
  9. Serum and brain metabolomic study reveals the protective effects of Bai-Mi-Decoction on rats with ischemic stroke
    • Authors: Yang, L., Su, X., Lu, F., Chen, J., Ma, X.
    • Year: 2022
    • Citations: 3
  10. Integration of pharmacodynamics and metabolomics reveals the therapeutic effects of 6-acetylacteoside on ovariectomy-induced osteoporosis mice
  • Authors: Liu, J., Ding, S., Yang, L., Chen, J., Ma, X.
  • Year: 2022
  • Citations: 3